Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2015

View Archived Issues

Phylogica's 1746-Omomyc fusion reduces tumor size in mouse model of breast cancer

Celyad provides update on C-Cure in Europe

Lundbeck reviews key events of third quarter 2015

Celgene offers pipeline update for third quarter 2015

Investigators present first-in-human results of JF-04 stent for coronary lesions

Squamous NSCLC response rate improved when necitumumab added to paclitaxel-carboplatin

RedHill Biopharma and IntelGenx confirm first European approval of Rizaport

FDA grants breakthrough therapy designation to SD-809 for tardive dyskinesia

Kite Pharma begins phase II trial of KTE-C19 mantle cell lymphoma

PhaseBio begins phase IIa study of once-weekly basal insulin, PE0-139

Caldan Therapeutics finances development of antidiabetic free fatty acid receptor modulators

FDA grants tentative approval to Xtampza for chronic pain

Pivotal phase III trial of RSV-F vaccine in older adults gets started by Novamax

Astellas to establish presence in ophthalmology through acquisition of Ocata Therapeutics

Pfizer reports development of dopamine D1 receptor ligands

Novartis discloses PI3K-gamma inhibitors

Idenix Pharmaceuticals divulges anti-HCV nucleosides

Gruenenthal patents Cav2.2 blockers

AbbVie presents CSF-1R inhibitors

Na-GST-1/Alhydrogel hookworm vaccine well tolerated and immunogenic in phase I studies

Nerviano Medical Sciences characterizes JAK-2 inhibitor NMS-P113

Biosimilar etanercept achieves endpoints in phase III psoriasis study

Fera Pharmaceuticals licenses U.S. rights to NicOx's naproxcinod

Janssen licenses rights to Hanmi's oxyntomodulin-based therapies

New genetic factors linked to persistent ADHD

ATR inhibitor VX-970 in advanced cancer

Proteome Sciences reports data on CK1d inhibitors for Alzheimer's disease

PZ-128 shows clinical promise

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...